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Available online 28 December 2015In this work we describe for the ﬁrst time the generation and characterization of human induced pluripotent
stem cells (hiPSCs) from peripheral blood mononuclear cells (PBMCs) and dermal ﬁbroblasts of a Primary
Hyperoxaluria Type I (PH1)-diagnosedpatientwith p.I244Tmutation,which is highly prevalent in Canary Islands
due to founder effect. Cell reprogramming was performed using non-integrative Sendai viruses containing the
Yamanaka factors and the generated PH1-hiPSC lines (PH1-PBMCs-hiPSC4F1 and PH1-Fib-hiPSC4F1) showed
normal karyotypes, silencing of the exogenous reprogramming factors, induction of the typical pluripotency-
associated markers and in vivo differentiation ability to the three germ layers.
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We have generated human induced pluripotent stem cell (hiPSC)
lines from peripheral blood mononuclear cells (PBMCs) and human
dermal ﬁbroblasts of a Primary Hyperoxaluria Type I (PH1)-diagnosed
patient with c.731TNC mutation (p.I244T) in AGXT gene, which is
highly prevalent in Canary Islands due to founder effect (Santana et al.
2003). PH1-PBMCs-hiPSC4F1 and PH1-Fib-hiPSC4F1 lines were
generated using the CytoTune®-iPS 2.0 Reprogramming System
(Life Technologies, Invitrogen), which includes the reprogramming
factors SOX2, POU5F1, cMYC and KLF4. This reprogramming system is
based on a modiﬁed and non-transmissible form of Sendai virus (SeV)
(Ban et al. 2011). Both PH1-hiPSC lines displayed a typical round
shape ESC-like morphology with small and tightly packed cells, with a
high nucleus/cytoplasm ratio and prominent nucleoli (Fig. 1A). The
presence of the c.731TNC mutation in AGXT gene was conﬁrmed
in both PH1-hiPSC lines (Fig. 1B) and the expression of several
pluripotency-associated markers was corroborated by qPCR (Fig. 1C),
immunoﬂuorescence (Fig. 2A) and FACS analyses (Fig. 2B). Moreover,
the absence of exogenous reprogramming transgenes was observed
by RT-PCR after 8–10 passages (Fig. 1D). Differentiation capacity
into three germ layers was demonstrated by in vivo teratoma forma-
tion (Fig. 3A). Finally, PH1-hiPSC lines showed normal karyotype
(46, XY) (Fig. 3B) and cell line identity was corroborated by DNA
ﬁngerprinting.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Characterization of PH1-hiPSC lines. (A) PH1-PBMCs-hiPSC4F1 and PH1-Fib-hiPSC4F1 cells display a typical round shape colony morphology with small, tightly packed cells.
(B) Genotyping of the PH1-hiPSC lines. Presence of the c.731TNC mutation in AGXT gene was analyzed sequencing the AGXT exon 7. (C) Endogenous pluripotency-associated markers
NANOG, POU5F1, SOX2, LIN28a, and DPPA4 were conﬁrmed by qPCR. Parental PBMCs and ﬁbroblasts were used as negative controls. (D) Silencing of exogenous reprogramming
factors was conﬁrmed by RT-PCR.
Fig. 2. Expression of pluripotency-associatedmarkers. (A) NANOG, POU5F1, SOX2 and TRA1-81 expression at protein level by immunoﬂuorescence. (B) Expression of TRA1-60 and SSEA4
by FACS analysis. Parental PBMCs and ﬁbroblasts were used as negative controls.
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Fig. 3.Differentiation capacity and genomic stability. (A) In vivo differentiation test by teratoma formation assay. The pictures show hematoxylin/eosin staining (H&E)with representative
tissues from the three germ layers. (B) Karyotype analysis of PH1-hiPSC lines depicting a normal 46XY karyotype.
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3.1. Ethical approval
All procedures described in this work were approved by the Univer-
sity of Navarra Ethical Committee aswell as by the Advisory Committee
for Human Tissue and Cell Donation and Use, according to the Spanish
and EU legislation. Fibroblast and peripheral blood mononuclear cells
(PBMCs) used for generation of the induced pluripotent stem cell line
were isolated from a PH1-diagnosed patient with c.731TNC mutation
in AGXT gene (p.I244T) after written informed consent.3.2. Cell culture
Human ﬁbroblasts were obtained from a skin biopsy by direct
seeding of small tissue fragments under coverslips. Cells were cultured
in gelatin-coated culture plates for a maximum of ﬁve passages before
reprogramming in Dulbecco's Modiﬁed Eagle Medium (DMEM, Sigma)
supplemented with 10% fetal bovine serum (FBS, Gibco), 0.1 mM non-
essential amino acids (NEAA, Gibco), 2 mM L-glutamine (Lonza), and
100 UI/mL penicillin/streptomycin (P/S, Lonza). Mononuclear cells
were obtained from peripheral blood collected in EDTA. Blood
sample was diluted in PBS and centrifuged with Ficoll Paque™
PLUS (GE Healthcare) to isolate PBMCs that were resuspended in
DMEM (Sigma) supplemented with 2% FBS (Gibco), 2 mM L-
glutamine (Lonza), and 100 UI/mL P/S (Lonza) before being directlyreprogrammed after isolation or frozen for further reprogramming
experiments.3.3. PH1-hiPSC generation
To induce cell reprogramming, isolated ﬁbroblasts or PBMCs were
exposed to Sendai viral (SeV) particles (Ban et al. 2011) included in
the CytoTune® 2.0 cellular reprogramming kit (Invitrogen, San Diego,
CA) according to the manufacturer's instructions. Brieﬂy, ﬁbroblasts
and PBMCs were infected with SeV at MOI of 3 and the following day,
viral particles were removed and infected PBMCswere seeded at differ-
ent densities (850, 1700 and 3400 cells/cm2) onto irradiated mouse
embryonic ﬁbroblast (iMEF) feeder cells in PBMCmedia. Infected ﬁbro-
blasts were cultured for 6 more days in ﬁbroblast culture media before
transfer onto iMEF feeder cells at the same densities. On the second
day after replating PBMC or ﬁbroblast media was replaced with Knock-
out DMEM (Gibco) supplemented with 20% Knockout serum replace-
ment (KSR, Gibco), 0.1 mM NEAA (Lonza), 2 mM L-glutamine (Lonza),
100 UI/mL P/S (Lonza), 0.1 mM b-mercaptoethanol (Gibco), and
5 ng/mL bFGF (Peprotech). Two to four weeks after transduction,
emerging iPSC colonies were picked individually and expanded on irra-
diated MEFs in the presence of 10 μM of ROCK inhibitor compound
GSK269962A (AxonMedChem). For some experiments iPSCs were
picked and cultured on feeder-free conditions using Matrigel™-coated
culture dishes (BD Biosciences) and Essential 8 culture media (Life
Technologies) according to the manufacturer's instructions. Cells were
Table 1
Primer sequences used in this study.
Gene Forward Reverse Applicationn
GAPDH ctggtaaagtggatattgttgccat tggaatcatattggaacatgtaaacc qPCR
DPPA4 tggtgtcaggtggtgtgtgg ccaggcttgaccagcatgaa qPCR
LIN28a ggaggccaagaaagggaatatga aacaatcttgtggccactttgaca qPCR
NANOG ccaacatcctgaacctcagc tgcgtcacaccattgctatt qPCR
POU5F1 ggaaggaattgggaacacaaagg aacttcaccttccctccaacca qPCR
SOX2 tggcgaaccatctctgtggt ccaacggtgtcaacctgcat qPCR
hAGXT_exon77 actcccgtgaaacaggacag ggggacagtgtttgtggaag genotyping
SeV ggatcactaggtgatatcgagc accagacaagagtttaagagatatgtatc silencing
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cells reached conﬂuence (Fig. 1A).
3.4. Genomic DNA extraction and genotyping
GenomicDNAwas isolated fromPH1-hiPSCs and parental cells using
NucleoSpin tissue kit (Macherey-Nagel). For genotyping 50 ng of DNA
was ampliﬁed using Platinum® Taq DNA Polymerase High Fidelity
(Invitrogen) using speciﬁc primers (Table 1) and the presence of the
c.731TNCmutation in AGXT genewas analyzed by sequencing (Fig. 1B).
3.5. RNA extraction and RT-qPCR
Total RNAwas isolatedwithMaxwell® 16 LEV simplyRNA Tissue Kit
(Promega) using a Maxwell® 16 Research Instrument (Promega) ac-
cording to the manufacturer's instructions. RNA concentration was de-
termined using a NanoDrop spectrophotometer (Thermo Scientiﬁc)
and RNA quality was tested using Bioanalyzer (Agilent). Complementa-
ry DNA (cDNA) was synthesized using PrimeScript™ RT reagent Kit
(Takara) according to the manufacturer's instructions. Quantitative
PCR (qPCR) primers (Table 1) were designed using Primer3 input soft-
ware and GAPDH was used as housekeeping gene. Expression of
pluripotency-associated markers was evaluated by qPCR (Fig. 1C).
Silencing of the exogenous reprogramming factors was analyzed by RT-
PCR following CytoTune®-iPS 2.0 Reprogramming kit manufacturer's
instructions (Invitrogen) (Fig. 1D).
3.6. Immunoﬂuorescence (IF)
IF was performed as described (Zapata-Linares et al. 2016). In brief,
PH1-hiPSCs were ﬁxed with 4% paraformaldehyde (PFA, Sigma),
permeabilized for 10 min with 1% TritonX-100 (Sigma) in PBS and
blocked with 5% bovine serum albumin (BSA) for 30 min at room tem-
perature. SOX2 (R&D), POU5F1 (Santa Cruz), NANOG (Abcam) and
TRA1-81 (Chemicon) primary antibodies were diluted in PBS/TBS with
1% BSA and incubated for 1 h at RT. FITC-conjugated and Cy3-
conjugated secondary antibodies (Sigma) were incubated for 1–1.5 h
at RT. Samples were visualized under an inverted ﬂuorescence micro-
scope (Nikon Eclipse Ti-S) (Fig. 2A).
3.7. Flow cytometry analysis
Pluripotency-associated markers were analyzed by FACS as described
(Zapata-Linares et al. 2016). Brieﬂy PH1-hiPSCswere dissociated by incu-
bation with TrypLE Express (Life Technologies) for 5 min. Then, hiPSCs
were suspended in FACSbuffer (5% FBS 2mMEDTA inPBS) and incubated
with PE-conjugated mouse anti-TRA1-60 and FITC-conjugated mouse
anti-SSEA-4 speciﬁc primary antibody (BD Biosciences) for 30 min at
4 °C. An irrelevant isotype-match antibodywas used as a negative control.
Then, the cells were washed with FACS buffer and stained with 7-
aminoactinomycin D (7-AAD, BD Bioscience) for 5 min at RT. Stained
cells were analyzed using a FACSCalibur (BD Bioscience) and FlowJo
software (FlowJo Enterpirse) (Fig. 2B).3.8. In vivo teratoma formation assay by PH1-hiPSCs
Teratomas were generated by subcutaneous injection as described
(Zapata-Linares et al. 2016). In brief, 2–5 × 106 PH1-hiPSCs cultured
on Matrigel were injected into the dorsal ﬂanks of 4–6 week-old male
immune-deﬁcient Rag2−/−γc−/−mice according to the ethical guide-
lines observed by the University of Navarra. About 4–6 weeks after
injection, tumors were dissected, ﬁxed in 10% formalin (Sigma),
parafﬁn-embedded, sectioned and stained with hematoxylin/eosin.
The presence of differentiated tissues representative of the three em-
bryonic germ layers was analyzed (Fig. 3A).
3.9. Karyotype analysis
Chromosomal analysis was performed by GTG-banding analysis at
CIMA LAB Diagnostics (CIMA, University of Navarra), according to the
International System Cytogenetics Nomenclature recommendations.
All PH1-hiPSC lines displayed a normal karyotype (46, XY) (Fig. 3B).
3.10. DNA ﬁngerprinting
DNA ﬁngerprinting was performed at the Genomics Core Facility
(CIMA, University of Navarra) in order to detect the pattern of short tan-
dem repeats (STRs) of PH1-hiPSC lines and its parenteral PBMCs and ﬁ-
broblast using AmpFlSTR® Identiﬁler® PCR Ampliﬁcation Kit (Applied
Biosystems). Multiplex PCR performed for the STRs Amelogenin,
CSF1PO, D13S317, D16S539, D5S818, D7S820, THO1, TPOX and vWA
conﬁrmed cell identity.
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